Ovarian Cancer Clinical Trial

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Summary

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Subjects with histologically/cytologically confirmed advanced malignancy (solid tumor) who must have exhausted all available standard therapy; or not a candidate for standard therapy.
Subject is able to provide written, informed consent before initiation of any study related procedures, and is able, in the opinion of the investigator, to comply with all the requirements of the study.
Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

Key Exclusion Criteria:

Prior treatment with a TIGIT inhibitor.
Symptomatic interstitial lung disease or inflammatory pneumonitis.
History of immune-related events that required immunotherapy treatment discontinuation.

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

90

Study ID:

NCT04354246

Recruitment Status:

Recruiting

Sponsor:

Compugen Ltd

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

START Midwest.
Grand Rapids Michigan, 49503, United States More Info
COM902 Study Director
Contact
415-373-0781
[email protected]
The Ohio State University Comprehensive Cancer Center.
Columbus Ohio, 43210, United States More Info
COM902 Study Director
Contact
415-373-0781
[email protected]
The University of Tennessee WEST Cancer Center.
Memphis Tennessee, 38138, United States More Info
COM902 Study Director.
Contact
415-373-0781
[email protected]
Mary Crowley Cancer Research
Dallas Texas, 75230, United States More Info
COM902 Study Director.
Contact
415-373-0781
[email protected]
MD Anderson Cancer Center.
Houston Texas, 77030, United States More Info
COM902 Study Director
Contact
415-373-0781
[email protected]
The START Center for Cancer Care.
San Antonio Texas, 78229, United States More Info
COM902 Study Director
Contact
415-373-0781
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

90

Study ID:

NCT04354246

Recruitment Status:

Recruiting

Sponsor:


Compugen Ltd

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.